95250-48-9 Usage
Chemical class
Matrix metalloproteinase inhibitors
A group of drugs that inhibit the activity of matrix metalloproteinases.
Experimental treatment
Cancer
Used as a potential treatment to inhibit the growth and spread of tumors.
Mechanism of action
Blocking matrix metalloproteinase enzyme
Inhibits the action of an enzyme responsible for the growth and spread of cancer cells.
Potential applications
Multiple sclerosis and arthritis treatment
Being investigated for its ability to reduce inflammation and tissue destruction in these diseases.
Chemical structure
1H-Purine-2,6-dione, 3,7-dihydro-7-[3-hydroxy-5-[4-[3-(phenylthio)propyl]-1-piperazinyl]pentyl]-1,3-dimethyl-
A complex structure based on a purine core with various functional groups attached.
Salt form
Dihydrochloride
The compound is in the form of dihydrochloride salts, which can improve its solubility and bioavailability.
Check Digit Verification of cas no
The CAS Registry Mumber 95250-48-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,5,2,5 and 0 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 95250-48:
(7*9)+(6*5)+(5*2)+(4*5)+(3*0)+(2*4)+(1*8)=139
139 % 10 = 9
So 95250-48-9 is a valid CAS Registry Number.
95250-48-9Relevant academic research and scientific papers
New Antihistaminic Theophylline or Theobromine Derivatives
Pascal, Jean-Claude,Beranger, Serge,Pinhas, Henri,Poizot, Alain,Desiles, Jean-Pierre
, p. 647 - 652 (2007/10/02)
A series of 3,4-dihydro-1,3-dimethyl-7--1H-purine-2,6-diones and 3,7-dihydro-3,7-dimethyl-1--1H-purine-2,6-diones was synthesized and evaluated for antihistaminic activity.Some of them displayed good inhibition of both histamine-induced bronchospasm in the anesthetized guinea pig at 10 μ/kg by the intravenous route and of passive cutaneous anaphylaxis in the rat at 10 mg/kg by the oral route.Comparison of the two most active compounds revealed a higher antihistaminic activity with the compounds containing a (phenylthio)propyl group (1 and 2) as compared with that containing a phenoxy group.Compound 2 piperazin-1-yl>-2-hydroxypropyl>-1H-purine-2,6-dione> was selected for clinical trials on the basis of a comparative pharmacological study with chloropheniramine, ketotifen, promethazine, and theophylline.
